5news.Indian news, all in one place

BREAKING

› EXCLUSIVE: Excel Entertainment teaming up with Kanika Dhillon for an intense thriller › Prime Video announces September 11 premiere for Nikkhil Advani’s The Revolutionaries › Bharatanatyam artiste Shweta Prachande navigates the many facets of water in ‘Apah’› No State should interfere in another State’s administration: D.K. Shivakumar › Bihari Lal Engineering IPO debut in focus: GMP hints at 40% listing pop › Jharkhand protest LIVE: Rahul Gandhi says heartening to see 'understanding' between students, Govt.; CBI probe demand continues › ‘Good goes up, bad goes down’: What this simple stair rule means for knee pain › Waste opportunity: Gobardhan scheme could be gamechanger for biofuel sector › Keralam CM flags off Vizhinjam port EXIM operations, says this opens State’s development gateway to world › Actor Yoo Ah-in is returning to the entertainment industry after a drug case › EXCLUSIVE: Excel Entertainment teaming up with Kanika Dhillon for an intense thriller › Prime Video announces September 11 premiere for Nikkhil Advani’s The Revolutionaries › Bharatanatyam artiste Shweta Prachande navigates the many facets of water in ‘Apah’› No State should interfere in another State’s administration: D.K. Shivakumar › Bihari Lal Engineering IPO debut in focus: GMP hints at 40% listing pop › Jharkhand protest LIVE: Rahul Gandhi says heartening to see 'understanding' between students, Govt.; CBI probe demand continues › ‘Good goes up, bad goes down’: What this simple stair rule means for knee pain › Waste opportunity: Gobardhan scheme could be gamechanger for biofuel sector › Keralam CM flags off Vizhinjam port EXIM operations, says this opens State’s development gateway to world › Actor Yoo Ah-in is returning to the entertainment industry after a drug case

Business

Biocon shares rise 2% after USFDA approval for Yesintek single-dose prefilled autoinjector

The Economic Times · 18 August 2026 at 12:26 pm

Biocon shares rose after its US subsidiary received supplemental FDA approval for Yesintek single-dose prefilled autoinjectors in two strengths.

The approval expands Biocon’s US immunology portfolio, with Yesintek used to treat conditions including plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.

Read the full article on The Economic Times ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on economictimes.indiatimes.com — the content belongs to The Economic Times.

More from The Economic Times

Tube Investments of India shares surge 8% after Q1 earnings. What Motilal Oswal is saying

The Economic Times · 2 h ago

Welspun Living shares surge 8%; stock gains 14% in 3 days. What’s driving the rally?

The Economic Times · 2 h ago

Colgate-Palmolive shares fall over 2% after Investor Day. What Goldman Sachs and other brokerages are saying

The Economic Times · 3 h ago

Hindustan Copper, Vedanta, other metal stocks slip up to 2% after sharp gains. Should you buy the dip or avoid?

The Economic Times · 3 h ago

More in Business

Bihari Lal Engineering IPO debut in focus: GMP hints at 40% listing pop

Business Standard · 13 min ago

Waste opportunity: Gobardhan scheme could be gamechanger for biofuel sector

Business Standard · 17 min ago

Pakistan top court orders former PM Imran Khan to be shifted to hospital

Business Standard · 30 min ago

Shiprocket IPO could offer over 30% listing pop; check post-debut strategy

Business Standard · 35 min ago

Paras Defence zooms 163% from March low; hits 52-week high on huge volume

Business Standard · 36 min ago

Hindustan Copper plans capital investment of ₹7,000 cr in next 5-6 yrs

Business Standard · 41 min ago